Dansereau R N, Line B R
Department of Pharmacy, Albany Medical Center Hospital, New York 12208, USA.
Clin Nucl Med. 2000 Mar;25(3):179-81. doi: 10.1097/00003072-200003000-00003.
Lymphoscintigraphy is an established means to determine the lymphatic drainage patterns from malignant tissues and edematous extremities. Unfortunately, there are no commercially available dedicated radiopharmaceuticals labeled for use in lymphoscintigraphy studies. The authors report a simple way to extemporaneously compound pharmaceutical-grade Tc-99m dextran 70 to meet this need. Pharmaceutical-quality Tc-99m dextran 70 injection is prepared by a simple rapid method from drug intermediates that are marketed as parenteral drug products. The radiolabeling process yields a product of high radiochemical purity, with good in vitro and in vivo stability. The authors illustrate the use of this product in a patient with melanoma to show the lymphatic drainage pattern before surgery. The method described permits rapid compounding of Tc-99m dextran 70 injection from drug components that are intended for parenteral administration. Tc-99m dextran 70 provides the option of performing lymphoscintigraphy in any clinical nuclear medicine setting.
淋巴闪烁造影术是确定恶性组织和肢体水肿的淋巴引流模式的既定方法。不幸的是，目前尚无市售的专门用于淋巴闪烁造影术研究的放射性药物。作者报告了一种简单的方法，可临时配制药用级99m锝标记的右旋糖酐70来满足这一需求。药用级99m锝标记的右旋糖酐70注射液是通过一种简单快速的方法，由作为注射用药品销售的药物中间体制备而成。放射性标记过程产生的产品具有高放射化学纯度，在体外和体内都具有良好的稳定性。作者举例说明了该产品在一名黑色素瘤患者中的应用，以显示手术前的淋巴引流模式。所描述的方法允许从用于注射给药的药物成分快速配制99m锝标记的右旋糖酐70注射液。99m锝标记的右旋糖酐70为在任何临床核医学环境中进行淋巴闪烁造影术提供了选择。
